23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function.
23ME-00610
CD200
CD200R1
cancer immunotherapy
immune checkpoint
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
9
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
epublish
Résumé
Immune checkpoint inhibition (ICI) has revolutionized cancer treatment; however, only a subset of patients benefit long term. Therefore, methods for identification of novel checkpoint targets and development of therapeutic interventions against them remain a critical challenge. Analysis of human genetics has the potential to inform more successful drug target discovery. We used genome-wide association studies of the 23andMe genetic and health survey database to identify an immuno-oncology signature in which genetic variants are associated with opposing effects on risk for cancer and immune diseases. This signature identified multiple pathway genes mapping to the immune checkpoint comprising CD200, its receptor CD200R1, and the downstream adapter protein DOK2. We confirmed that CD200R1 is elevated on tumor-infiltrating immune cells isolated from cancer patients compared to the matching peripheral blood mononuclear cells. We developed a humanized, effectorless IgG1 antibody (23ME-00610) that bound human CD200R1 with high affinity (K
Identifiants
pubmed: 37288324
doi: 10.1080/2162402X.2023.2217737
pii: 2217737
pmc: PMC10243377
doi:
Substances chimiques
Immunoglobulins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2217737Informations de copyright
© 2023 23andMe. Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
XF, YH, CM, ELL, TP, AZ, MP, SRM, DG, MS, CCL: Employees of 23andMe JF, CB, CL, ZY, WC, AC: Employees of 23andMe at the time this work was performed
Références
J Immunol. 2004 Dec 1;173(11):6786-93
pubmed: 15557172
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Science. 2000 Dec 1;290(5497):1768-71
pubmed: 11099416
Cancer Cell. 2020 Apr 13;37(4):443-455
pubmed: 32289269
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
J Immunol. 2009 Oct 15;183(8):4879-86
pubmed: 19786546
Cancers (Basel). 2011 Dec 16;3(4):4281-93
pubmed: 24213139
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34326171
Nat Rev Drug Discov. 2022 Aug;21(8):551
pubmed: 35804044
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
J Pathol. 2021 Jul;254(4):418-429
pubmed: 33748968
Sci Immunol. 2018 May 18;3(23):
pubmed: 29776993
Mol Immunol. 2008 Feb;45(4):1126-35
pubmed: 17714785
PLoS One. 2016 Sep 09;11(9):e0161779
pubmed: 27610613
Sci Transl Med. 2023 Jan 18;15(679):eabn5029
pubmed: 36652534
Curr Opin Immunol. 2012 Apr;24(2):233-8
pubmed: 22264927
J Immunother Cancer. 2019 Aug 23;7(1):227
pubmed: 31443741
Nat Commun. 2021 May 5;12(1):2526
pubmed: 33953190
Immunity. 2021 Feb 9;54(2):367-386.e8
pubmed: 33567262
J Immunol. 2003 Sep 15;171(6):3034-46
pubmed: 12960329
Allergy. 2017 Jul;72(7):1081-1090
pubmed: 28106273
Cancer Immunol Res. 2014 Sep;2(9):846-56
pubmed: 24872026
Nat Genet. 2015 Aug;47(8):856-60
pubmed: 26121088
J Virol. 2012 Jun;86(11):6246-57
pubmed: 22491458